UBS Group Cuts United Therapeutics (NASDAQ:UTHR) Price Target to $385.00

United Therapeutics (NASDAQ:UTHR) had its price target lowered by UBS Group from $410.00 to $385.00 in a research note published on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

Other equities analysts have also issued reports about the stock. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $314.00 price target (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. HC Wainwright reaffirmed a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a research report on Monday, May 5th. Morgan Stanley raised their price target on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 1st. Bank of America lowered their price target on shares of United Therapeutics from $321.00 to $315.00 and set a “neutral” rating on the stock in a research report on Wednesday, June 11th. Finally, JPMorgan Chase & Co. lowered their price target on shares of United Therapeutics from $355.00 to $350.00 and set an “overweight” rating on the stock in a research report on Thursday, May 1st. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $386.15.

United Therapeutics Price Performance

Shares of UTHR opened at $295.22 on Monday. The firm has a market capitalization of $13.32 billion, a PE ratio of 11.78, a PEG ratio of 6.37 and a beta of 0.53. The company’s 50-day moving average is $301.18 and its 200-day moving average is $323.65. United Therapeutics has a fifty-two week low of $266.98 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, topping analysts’ consensus estimates of $6.29 by $0.34. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The business had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. During the same period last year, the firm earned $6.17 earnings per share. United Therapeutics’s revenue for the quarter was up 17.2% compared to the same quarter last year. Analysts predict that United Therapeutics will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Nilda Mesa sold 645 shares of the firm’s stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total value of $187,043.55. Following the sale, the director directly owned 4,883 shares in the company, valued at approximately $1,416,021.17. This trade represents a 11.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 26th. The shares were sold at an average price of $285.70, for a total transaction of $3,142,700.00. Following the completion of the sale, the executive vice president owned 36,781 shares in the company, valued at approximately $10,508,331.70. The trade was a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 80,681 shares of company stock worth $23,951,939 in the last quarter. Corporate insiders own 10.30% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Wealthfront Advisers LLC boosted its stake in shares of United Therapeutics by 2,090,573.5% in the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock valued at $6,462,018,000 after purchasing an additional 18,313,424 shares in the last quarter. Vanguard Group Inc. boosted its position in United Therapeutics by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 4,457,135 shares of the biotechnology company’s stock worth $1,374,001,000 after buying an additional 15,312 shares during the period. FMR LLC boosted its position in United Therapeutics by 36.5% during the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company’s stock worth $519,170,000 after buying an additional 393,777 shares during the period. Geode Capital Management LLC boosted its position in United Therapeutics by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company’s stock worth $401,184,000 after buying an additional 44,277 shares during the period. Finally, AQR Capital Management LLC boosted its position in United Therapeutics by 0.8% during the 4th quarter. AQR Capital Management LLC now owns 975,444 shares of the biotechnology company’s stock worth $344,176,000 after buying an additional 7,710 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.